Microchip patented which separates and extracts tumor cells in the blood
Ikerlan-IK4 and Mondragón Unibertsitatea are taking part in a project initiated by the Spanish National Research Council, CSIC, and which has developed a microchip capable of separating and extracting tumour cells in the blood stream by means of ultrasonic waves. The Foundation General Hospital of the University of Elche, together with researcher Alfredo Carrato, has also collaborated on this project.
The patented microchip has the size of a one euro coin, incorporating a small channel along which a sample of blood containing the patient's tumour cells flows. By means of ultrasonic waves focused on a specific zone, these cells, having a density and size different from the rest, concentrate at the point from where they are gathered.
The device, made of plastic, has potential advantages in the detection of metastasis in its initial phases, and in the control of the effectiveness of the therapy applied to cancer patients. It is made up of an acoustic wave piezoelectric generator, a microchip and a fluidic capsule.
Another of the unique features is that the process is totally non-invasive, given that there is no need to introduce any foreign object into the blood sample in order to detect tumour cells circulating in the blood. Moreover, it maintains the properties of the cells so that subsequent studies or biomolecular analyses can be carried out.
The next stage is developing an industrial-scale prototype. To this end, the research team is already working on perfecting the microchip, and on developing a system for the automatic detection and count of the tumour cells.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
John_Lattimer

We are much more unique than assumed

How Alzheimer’s could occur - Protein spheres in the nucleus give wrong signal for cell division
What stress does to the brain
EPA to Grant Merck’s Patent Application for CRISPR Technology - Related patent application recently awarded in Australia
Rebuilding the evolutionary history of HIV-1 unravels a complex loop
C-LEcta lays foundation for further growth and closes financing round - New CFO Thomas Pfaadt to manage and support growth

How a SARS-CoV-2 infection can become severe COVID-19 - Severity is linked to disruption of the endothelial barrier and can be measured by looking at inflammatory and endothelial plasma proteins
Finnish twin study yields new information on how fat cells cope with obesity
Texas A&M team finds neuron responsible for alcoholism
SUTENT Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET) - First Targeted Therapy Approved for the Treatment of Pancreatic NET in Europe
